Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open-label, Single-arm, Phase II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia

Next Previous
Trial Profile

A Multicentre, Open-label, Single-arm, Phase II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hetrombopag (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 13 Dec 2022 Results of post-hoc analysis assessing the impact of hetrombopag on iron metabolism in patients with severe aplastic anemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 08 Dec 2020 Status changed to completed, according to results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2020 Results (data cutoff date: 12 Jun 2020) from phase II portion of this trial reporting 24 out of 55 received hetrombopag met primary endpoint, achieving at least one lineage hematologic response at week 18 after initiation of treatment presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top